Clinical Trials Logo

PDAC clinical trials

View clinical trials related to PDAC.

Filter by:
  • None
  • Page 1

NCT ID: NCT06445062 Recruiting - Colorectal Cancer Clinical Trials

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Start date: May 24, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The first three subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel

NCT ID: NCT06151223 Recruiting - Pancreatic Cancer Clinical Trials

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

Start date: July 13, 2021
Phase:
Study type: Observational [Patient Registry]

This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying early stages of pancreatic cancer, as well as people at high-risk.The study also aims to provide a platform for development of an interventional protocol for early detection of PDAC.

NCT ID: NCT06122896 Recruiting - Pancreatic Cancer Clinical Trials

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Start date: November 21, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.

NCT ID: NCT05895214 Not yet recruiting - Surgery Clinical Trials

Mesopancreas Study in Pancreatic Cancer

MESOPANC-01
Start date: June 1, 2023
Phase:
Study type: Observational [Patient Registry]

After the Introduction of the pathological circumferential resection margin (CRM status by LEEPP Protocol), residual cancer (R1 resection) was most often found in the dorsal and medial resection margins. Yet only the medial resection margin is preoperatively evaluated during staging, while the dorsal resection margin which embeds the mesopancreatic fat and thus resembles the area of the mesopancreas, is not considered during preoperative assessment for resectability. Local recurrence is similarly prevalent as systemic relapse, and revised lower rates of R0CRM- resections through the LEEPP protocol explained the poor local tumor control. The aim of this study is to interdisciplinary approach the circumferential infiltration status of the PDAC concentrating foremost on the mesopancreas of the dorsal resection margin by including anatomic and embryologic derived perspectives.

NCT ID: NCT05642962 Recruiting - Pancreatic Cancer Clinical Trials

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Start date: November 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight. Other study goals are to explore two different dosing schedules of pancrelipase and to evaluate pancrelipase in people who do not have symptoms of EPI.

NCT ID: NCT05631574 Recruiting - Colorectal Cancer Clinical Trials

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Start date: January 12, 2023
Phase: Phase 1
Study type: Interventional

A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).

NCT ID: NCT05355298 Recruiting - Pancreatic Cancer Clinical Trials

ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer

Start date: May 31, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicentre, open label, two-part study to determine whether the focal adhesion kinase (FAK) inhibitor AMP945, when given prior to dosing with gemcitabine and nab-paclitaxel, improves response to therapy in first-line patients with unresectable or metastatic pancreatic cancer. Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Part B will determine the efficacy of the AMP945 regimen at the RP2D, and will be run as a Simon Two-stage design; Stage 1 will enrol 26 participants. If ≤5 of the 26 participants show an objective response, then recruitment will be paused and a detailed analysis of futility will be performed. If the study is deemed futile, recruitment will cease. If the study is determined to be not futile or >5 of the 26 participants show an objective response, recruitment will continue, and an additional 24 participants will be enrolled in Stage 2.

NCT ID: NCT05275985 Recruiting - PDAC Clinical Trials

68Ga-FAPI PET/CT in Pancreatic Ductal Carcinoma

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts (CAFs), which constitutes a major proportion of cells within the tumor microenvironment, especially in primary pancreatic ductal carcinoma (PDAC). In this prospective study, we aimed to evaluate the performance and value of 68Ga-FAPI-04 PET/CT in the patients with PDAC.

NCT ID: NCT04605237 Recruiting - Pancreatic Cancer Clinical Trials

Pancreatic Cancer Recurrence in the Netherlands

Start date: January 1, 2014
Phase:
Study type: Observational

The aim of this nationwide, observational cohort study is to evaluate current surveillance strategies after primary resection of pancreatic ductal adenocarcinoma (PDAC) in the Netherlands, with regard to the detection, treatment and survival of PDAC recurrence.